Related Experiment Videos

Effect of monthly atorvastatin treatment on hemostasis

B Okopien1, R Krysiak, Z S Herman

  • 1Department of Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.

International Journal of Clinical Pharmacology and Therapeutics
|December 16, 2004
PubMed

Insights

Atorvastatin treatment quickly improved key blood clotting factors in hypercholesterolemia patients, independent of its cholesterol-lowering effects. This suggests statins offer broader cardiovascular benefits beyond lipid reduction.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Hematology

Background:

  • 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are crucial for cardiovascular disease prevention.
  • Beyond lipid reduction, statins exhibit pleiotropic effects beneficial for cardiovascular health.
  • Hemostatic factors are implicated in cardiovascular risk, but their modulation by statins requires further investigation.

Purpose of the Study:

  • To evaluate the impact of 30-day atorvastatin therapy on major hemostatic risk factors in patients with primary hypercholesterolemia.
  • To assess changes in fibrinogen, PAI-1 levels, and factor VII coagulant activity.
  • To determine if atorvastatin's hemostatic effects are linked to its lipid-lowering capabilities.

Main Methods:

  • A study involving 18 hypercholesterolemic patients and 12 matched controls.
  • Administration of atorvastatin (20 mg/d) for 30 days to the patient group.
  • Measurement of lipid profiles, fibrinogen, PAI-1, and factor VII activity before and after treatment.

Main Results:

  • Hypercholesterolemic patients showed elevated PAI-1 levels and factor VII activity compared to controls.
  • Atorvastatin significantly reduced total cholesterol, LDL cholesterol, and oxidized LDL.
  • Atorvastatin also decreased PAI-1 levels and factor VII activity, with a trend towards reduced fibrinogen.
  • These hemostatic improvements were independent of the observed lipid-lowering effects.

Conclusions:

  • Atorvastatin demonstrates rapid, beneficial, and multifaceted non-lipid-related effects on hemostasis.
  • These findings suggest a novel mechanism for statin efficacy in cardiovascular disease prevention.
  • Further research is warranted to explore the clinical implications of these hemostatic modulations.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...